Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06652958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 30, 2026 (before its estimated September 9, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 1 to 2v7
  2. Trial status: Recruiting to Active, Not Recruiting Study sites: 2 to 1 · Primary completion date: Feb 1, 2027 to Sep 9, 2026 · Completion date: Feb 3, 2027 to Sep 9, 2026 · 3 morev6 Show 6 more changesShow less
    • Study sites: 2 to 1
    • Primary completion date: Feb 1, 2027 to Sep 9, 2026
    • Completion date: Feb 3, 2027 to Sep 9, 2026
    • Eligibility criteria shortened, about 46 words
    • Secondary endpoints revised (39)
    • Primary endpoints revised (7)

    See this version in full on ClinicalTrials.gov ↗

  3. Interventions: VH4527079 (Biological), rHuPH20 (Biological) to VH4527079 (Biological) Secondary endpoints revised (39) · Study arms: 14 to 9 · Eligibility criteria shortened, about 1 wordv5 Show 3 more changesShow less
    • Secondary endpoints revised (39)
    • Study arms: 14 to 9
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Enrollment target: 86 to 102 Interventions: VH4527079 (Biological) to VH4527079 (Biological), rHuPH20 (Biological) · Eligibility criteria expanded, about 55 words · Secondary endpoints revised (39) · 1 morev4 Show 4 more changesShow less
    • Interventions: VH4527079 (Biological) to VH4527079 (Biological), rHuPH20 (Biological)
    • Eligibility criteria expanded, about 55 words
    • Secondary endpoints revised (39)
    • Study arms: 9 to 14

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Active, Not Recruiting to Recruiting Primary completion date: May 28, 2026 to Feb 1, 2027 · Completion date: Jun 2, 2026 to Feb 3, 2027 · Site details revised at 2 of 2 sitesv3 Show 3 more changesShow less
    • Primary completion date: May 28, 2026 to Feb 1, 2027
    • Completion date: Jun 2, 2026 to Feb 3, 2027
    • Site details revised at 2 of 2 sites
  6. Trial status: Recruiting to Active, Not Recruiting Site details revised at 2 of 2 sitesv2 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single dose administration of VH4527079 by subcutaneous (SC) injection or by intravenous (IV) infusion in healthy adult participants and multiple dose administration by IV infusion in healthy adult participants and in Persons with HIV (PWH).
Trial Details
NCT Number NCT06652958
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 102 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov